Overview of Rubicon Research Ltd IPO
Rubicon Research Ltd IPO is a public offering by a company with a strong international presence. Rubicon Research offers integrated solutions in pharmaceutical R&D, formulations, licensing, and contract manufacturing. Its subsidiaries in the US, Canada, Singapore, and Australia expand the company’s global reach.
This IPO provides an opportunity for investors to participate in the growth of a company with a proven track record in research and development.
Rubicon Research IPO Price and Investment Details
The Rubicon Research IPO price is set in the range of ₹461 – ₹485 per share, with a minimum lot size of 30 shares. This makes the minimum retail investment around ₹14,550.
Investors looking to get exposure to the pharmaceutical research space can plan their investment based on this pricing. The IPO also reflects potential market value as seen in the Rubicon Research IPO GMP, currently around ₹42 per share.
Rubicon Research IPO Date and Listing Timeline
The Rubicon Research IPO date is scheduled from October 9 to October 13, 2025. The tentative allotment date is October 14, 2025, and listing is expected on October 16, 2025 on BSE and NSE.
Marking these dates is crucial for retail investors aiming to secure shares during the subscription period.
Financial Highlights of Rubicon Research Ltd
Rubicon Research has demonstrated strong financial performance in FY25:
-
Total Income: ₹1,296.22 crore
-
Profit After Tax (PAT): ₹134.36 crore
-
EBITDA: ₹267.89 crore
-
Net Worth: ₹540.98 crore
-
Debt/Equity Ratio: 0.73
-
ROE: 29.02%
These metrics indicate robust financial health, making the Rubicon Research Ltd IPO attractive to investors seeking growth and stability.
Purpose of the IPO
The company plans to utilize the IPO proceeds for:
-
Repayment of borrowings – ₹310 crore
-
Funding acquisitions and general corporate purposes – ₹190 crore
This strategy is aimed at strengthening the balance sheet and supporting future expansion.
Key Investment Considerations
Investing in the Rubicon Research IPO offers several potential advantages:
-
Global Reach: Operations in multiple international markets.
-
Diversified Services: Covers R&D, licensing, and manufacturing.
-
Strong Fundamentals: Healthy margins, growing PAT, and positive EBITDA.
-
Potential Listing Gains: Indicated by the Rubicon Research IPO GMP.
However, investors should also be aware of regulatory risks and past fluctuations in financial performance.
Summary of Key Details
-
Rubicon Research IPO price: ₹461 – ₹485 per share
-
Lot Size: 30 shares (~₹14,550 minimum)
-
Rubicon Research IPO date: October 9–13, 2025
-
Allotment Date: October 14, 2025 (tentative)
-
Listing Date: October 16, 2025 (tentative)
-
Rubicon Research IPO GMP: ₹42 per share
This IPO is an opportunity for investors to participate in a high-growth pharmaceutical R&D firm while keeping track of market trends and IPO updates.
For more insights, Rubicon Research IPO price updates, subscription guidance, and detailed financial analysis, visit Finowings.com.
